GERNGeron Corporation

GERN Stock Price, Valuation & Chart | Geron Corporation

Compare

$1.590+0.11 (+7.43%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology GERN intrinsic value GERN calculated fair value vs price

Overview Financials Dividends Ratios

GERN Historical price chart

GERN Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization1.02B

PE Ratio-17.67

EPS-0.09

Trading Volume26.86M

Today's High/Low1.61/1.49

Dividend Yield0.00

52 Week High/Low2.01/1.04

Shares Outstanding641.52M

GERN Financial Statement

GERN Analyst ratings

GERN Analysis & performance metrics

GERN Company profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It…

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the…

GERN Management team

Name

Position

Scott Samuels

Executive Vice President, Chief Legal Officer & Secretary

Aron Feingold

Vice President of Investor Relations & Corporate Communications

Michelle J. RobertsonCFO

Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer

Joseph Emile Eid M.D.

Executive Vice President of Research & Development

Andrew J. Grethlein Ph.D.COO

Executive Vice President & Chief Operating Officer

James Ziegler M.B.A.

Executive Vice President & Chief Commercial Officer

Shannon T. Odam

Executive Vice President & Chief People Officer

Dawn Carter BirCEO

Interim President & Chief Executive Officer and Director

Name

Position

Scott Samuels

Executive Vice President, Chief Legal Officer & Secretary

Aron Feingold

Vice President of Investor Relations & Corporate Communications

Michelle J. RobertsonCFO

Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer

Joseph Emile Eid M.D.

Executive Vice President of Research & Development

Andrew J. Grethlein Ph.D.COO

Executive Vice President & Chief Operating Officer

James Ziegler M.B.A.

Executive Vice President & Chief Commercial Officer

Shannon T. Odam

Executive Vice President & Chief People Officer

Dawn Carter BirCEO

Interim President & Chief Executive Officer and Director

Management Team

Scott Samuels

Executive Vice President, Chief Legal Officer & Secretary

Aron Feingold

Vice President of Investor Relations & Corporate Communications

Michelle J. RobertsonCFO

Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer

Joseph Emile Eid M.D.

Executive Vice President of Research & Development

Andrew J. Grethlein Ph.D.COO

Executive Vice President & Chief Operating Officer

James Ziegler M.B.A.

Executive Vice President & Chief Commercial Officer

Shannon T. Odam

Executive Vice President & Chief People Officer

Dawn Carter BirCEO

Interim President & Chief Executive Officer and Director

Management

Scott Samuels

Executive Vice President, Chief Legal Officer & Secretary

Aron Feingold

Vice President of Investor Relations & Corporate Communications

Michelle J. RobertsonCFO

Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer

Joseph Emile Eid M.D.

Executive Vice President of Research & Development

Andrew J. Grethlein Ph.D.COO

Executive Vice President & Chief Operating Officer

James Ziegler M.B.A.

Executive Vice President & Chief Commercial Officer

Shannon T. Odam

Executive Vice President & Chief People Officer

Dawn Carter BirCEO

Interim President & Chief Executive Officer and Director

Total 8 executives

GERN Frequently asked questions

What is Geron Corporation (GERN) Stock Price?

Current stock price of Geron Corporation (GERN) stock is $1.590. The stock price is +7.43% higher in the session. The intraday range can be seen from this page. Volume of Geron Corporation (GERN) stock is 26.86M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Geron Corporation (GERN) stock price going up or down today?

The stock price of Geron Corporation (GERN) can change with earnings, company news, and overall market sentiment. Geron Corporation operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Geron Corporation stock expensive at its current price?

Whether Geron Corporation looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for GERN on this page is -17.67. EPS on this page is -0.09. Compare those figures with peers and growth expectations before deciding if the current Geron Corporation price is justified.

How has the stock price of Geron Corporation (GERN) performed historically?

Historical performance for Geron Corporation (GERN) is shown on the price chart on this page. Review multi-period moves alongside volume to see how GERN reacted to past earnings and market events.

Should I buy Geron Corporation (GERN) stock, at this price?

Buying Geron Corporation (GERN) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.